rcca-header
Clinical Trials

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies
Phase
Division (Location)
East Brunswick, NJ, Freehold, NJ, Somerville, NJ
Study ID
NCT#
Brief Description
Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.